Eliem Therapeutics (ELYM)
(Delayed Data from NSDQ)
$6.99 USD
-0.37 (-5.03%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $6.96 -0.03 (-0.43%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for Eliem Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | NA |
Cost Of Goods | 0 | 0 | 0 | 0 | NA |
Gross Profit | 0 | 0 | 0 | 0 | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 40 | 45 | 36 | 21 | 0 |
Income After Depreciation & Amortization | -40 | -45 | -36 | -21 | 0 |
Non-Operating Income | 5 | 0 | -12 | 0 | NA |
Interest Expense | 0 | 0 | 0 | 0 | NA |
Pretax Income | -35 | -45 | -47 | -21 | NA |
Income Taxes | 0 | 0 | 0 | 0 | NA |
Minority Interest | 0 | 0 | 0 | 0 | NA |
Investment Gains/Losses | 0 | 0 | 0 | 0 | NA |
Other Income/Charges | 0 | 0 | 0 | 0 | NA |
Income From Cont. Operations | -35 | -45 | -47 | -21 | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | NA |
Net Income (GAAP) | -35 | -45 | -47 | -21 | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -43 | -45 | -35 | -21 | 0 |
Depreciation & Amortization (Cash Flow) | -2 | 0 | 0 | 0 | NA |
Income After Depreciation & Amortization | -40 | -45 | -36 | -21 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 26.99 | 26.31 | 12.26 | NA | NA |
Diluted EPS Before Non-Recurring Items | -1.30 | -1.72 | -4.24 | NA | NA |
Diluted Net EPS (GAAP) | -1.30 | -1.72 | -4.24 | NA | NA |
Fiscal Year end for Eliem Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 56.38 | 3.00 | 5.13 | 5.01 | 6.72 |
Income After SG&A, R&D, and Dept/Amort Expenses | -56.38 | -3.00 | -5.13 | -5.01 | -6.72 |
Non-Operating Income | 1.48 | 1.31 | 1.48 | 1.03 | 1.49 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -54.89 | -1.70 | -3.64 | -3.97 | -5.22 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -54.89 | -1.70 | -3.64 | -3.97 | -5.22 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -54.89 | -1.70 | -3.64 | -3.97 | -5.22 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 30.33 | 27.64 | 26.99 | 27.00 | 26.84 |
Diluted EPS Before Non-Recurring Items | -1.81 | -0.06 | -0.13 | -0.15 | -0.19 |
Diluted Net EPS (GAAP) | -1.81 | -0.06 | -0.12 | -0.15 | -0.19 |